Testing azer-cel, a donor-derived CAR T therapy, in adults with relapsed blood cancers
Tests azer-cel, a CAR T therapy, in adults with returned lymphoma or leukemia.
Key facts
- Who runs it
- Imugene Limited
- Where
- Atlanta, Baltimore, Boston, Dallas, Milwaukee, Minneapolis, New York, Providence, and Tampa, United StatesSee the 10 sitesAlso in 1 other country, 5 sites
- Trial code
- Registry title
- Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 135 people, planned
- Started
- 11 Mar 2019
- Expected to end
- Jun 2027
- Type of study
- Interventional, 7 groups
- Treatments tested
- Azer-cel
- Fludarabine
- Cyclophosphamide
- IL-2
- Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib
- Record updated
- 8 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose B-cell lymphoma, CLL/SLL or B-cell acute lymphoblastic leukemia (CD19-positive) came back or did not respond to earlier treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Relapsed or refractory CD19+ B-ALL, aggressive B-cell NHL (for example DLBCL, HGBCL, FL, MZL, WM) or CLL/SLL. Lymphoma must be confirmed by a biopsy from the last relapse.
- Earlier treatment
- Lymphoma: at least 1-2 earlier lines of therapy (depending on subtype) but no more than 7. One group must have had autologous CD19 CAR T therapy and then relapsed. Another group must be taking a BTK inhibitor and have progressed on it.
- Biomarker or test result
- The cancer must be CD19-positive. Participants must be negative for HIV antibody.
Main reasons for not taking part
- Burkitt cell (L3 ALL) or mixed-lineage acute leukemia
- Active central nervous system disease (except primary CNS lymphoma)
- History of another primary cancer
- Stem cell transplant within 90 days before screening, or active graft-versus-host disease
- CD19-directed therapy other than autologous CAR T within 90 days of the planned start of lymphodepletion
The registry criteria, word for word
Show all 51 criteriaShow less
Who can take part
- Criteria for B-ALL:
- Participant has confirmed unequivocal r/r CD19+ B-ALL; Criteria for NHL and CLL/SLL:
- Participant has unequivocal aggressive CD19+ r/r B-cell NHL that is confirmed by tumor biopsy tissue from last relapse after CD19-directed therapy; For Phase 1 Dose Escalation:
- Diffuse large B-cell lymphoma (DLBCL) including Richter's transformation
- Follicular lymphoma (FL) including Grade 3 or transformed FL
- High-grade B-cell lymphoma (HGBCL)
- Primary mediastinal lymphoma; For Phase 1b Dose Expansion (CAR T-relapsed cohort):
- DLBCL not otherwise specified (NOS)
- HGBCL
- DLBCL transformed from the following indolent lymphoma subtypes (FL, Marginal Zone lymphoma [MZL], and Waldenstrom's Macroglobulinemia [WM])
- Other large B-cell lymphoma (LBCL) subtypes may be enrolled with approval from the Medical Monitor
- Participants previously treated with CD19-directed autologous CAR T therapies have received no more than 2 lines of therapy after administration of their previous CAR T product
- For the expansion CAR T-relapsed cohort only: Participants must have received autologous CD19-directed CAR T therapy and demonstrated clinical response to the treatment at Day 28 or later, followed by relapse or progression; For Phase 1b dose expansion (CAR T-naive cohort and Con-BTKi cohort):; For indication with an approved autologous CAR T-cell therapy, participants must be ineligible for or unable to access autologous CAR T-cell therapy
- DLBCL NOS
- DLBCL transformed from the following indolent lymphoma subtypes (FL, MZL, and WM)
- HGBCL
- FL (Grade 1-3a)
- MZL that is fluorodeoxyglucose (FDG)-avid on positron emission tomography (PET) scan
- WM
- CLL/SLL
- Primary central nervous system (CNS) lymphoma (PCNSL)
- Other LBCL subtypes may be enrolled with approval from the Medical Monitor
- Participant must have received at least 1-2 prior lines of therapy, depending on histological subtype but no more than 7 systemic lines of anti-cancer therapy; Participants enrolling into the Con-BTKi cohort must:
- Be receiving a BTKi (as a monotherapy or combination therapy) as the last, systemic anti-cancer regimen before study entry. Alternatively, if previously refractory to one or more BTK inhibitor(s) and the last systemic anti-cancer therapy before study entry did not include a BTKi, one of the previous BTK inhibitors may be used
- Have radiologic or clinical disease progression while on the BTKi
- Agree to remain on BTKi therapy during the protocol-defined BTKi treatment window
- Have been tolerant to BTKi therapy; Criteria for both B-ALL, NHL, and CLL/SLL:
- Eastern Cooperative Oncology Group performance status score of 0 or 1
- An estimated life expectancy of at least 12 weeks according to the investigator's judgment
- Seronegative for human immunodeficiency virus antibody
- Participant has adequate bone marrow, renal, hepatic, pulmonary, and cardiac function
Who cannot take part
- Requirement for urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression
- History of hepatitis B or hepatitis C currently receiving ongoing antiviral therapy; Any known uncontrolled cardiovascular disease at the time of Screening that, in the investigator's opinion, renders the participant ineligible
- History of hypertension crisis or hypertensive encephalopathy within 3 months prior to Screening
- History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome, or any other known bone marrow failure syndrome
- Participant has received stem cell transplant within 90 days before Screening
- Participant has received a systemic biologic agent for treatment of the disease under study within 28 days of LD, other systemic anti-cancer therapy within 10 days or 5 half-lives (whichever is shorter) of LD, and no pulse steroid for disease control within 3 days of LD
- Radiotherapy within 4 weeks before Screening
- Participant has received live vaccine within 4 weeks before Screening. Note: Non-live virus vaccines are not excluded
- Participant has received CD19-directed therapy other than autologous CD19-directed CAR T therapy within 90 days of the anticipated start date of LD; Additional criteria apply
- No active CNS disease, excluding PCNSL
- History of another primary malignancy
- Any form of primary immunodeficiency (for example, severe combined immunodeficiency disease)
- History of severe immediate hypersensitivity reaction to any of the agents used in this study
- Presence of a CNS disorder that, in the opinion of the investigator, renders the participant ineligible for treatment
- Active uncontrolled autoimmune disease requiring active immunosuppression at the time of Screening (excluding participants needing steroids for physiologic replacement)
- Participant has active graft-versus-host disease (GvHD) symptoms
- Criteria for B-ALL:
- Burkitt cell (L3 ALL) or mixed-lineage acute leukemia; Criteria for NHL:
- Active hemolytic anemia; Criteria for B-ALL and NHL:
- Presence of pleural/peritoneal/pericardial catheter, as well as permeant biliary and ureteral stents (does not apply to intravenous lines)
Where in United States
Also in 1 other country, 5 sites
- Northside Hospital Cancer InstituteAtlanta, United StatesContact: Clinical TrialsTaking people
- Winship Cancer Institute, Emory UniversityAtlanta, United StatesContact: Clinical TrialsTaking people
- University of MarylandBaltimore, United StatesContact: Clinical TrialsTaking people
- Tufts Medical CenterBoston, United StatesContact: Clinical TrialsTaking people
- Baylor University Medical CenterDallas, United StatesContact: Clinical TrialsTaking people
- Medical College of WisconsinMilwaukee, United StatesContact: Clinical TrialsTaking people
- University of MinnesotaMinneapolis, United StatesContact: Clinical ResearchTaking people
- Columbia University Irving Medical Center/New York Presbyterian HospitalNew York, United StatesContact: Clinical TrialsTaking people
- Lifespan Cancer Institute at Rhode Island HospitalProvidence, United StatesContact: Clinical TrialsTaking people
- H Lee Moffitt Cancer CenterTampa, United StatesContact: Clinical ResearchTaking people
About the trial
What the trial wants to find out
This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.
The 7 groups in the trial
- Phase 1 Dose Escalation: Azer-cel Dose Level 1Treatment being tested
Azer-cel, 3 x 10\^5 CAR T cells per kilogram (kg) body weight. Route of Administration: Intravenous infusion
Treatment: Azer-cel, Fludarabine, and Cyclophosphamide
- Phase 1 Dose Escalation: Azer-cel Dose Level 2Treatment being tested
Azer-cel, 1 x 10\^6 CAR T cells per kg body weight. Route of Administration: Intravenous infusion
Treatment: Azer-cel, Fludarabine, and Cyclophosphamide
- Phase 1 Dose Escalation: Azer-cel Dose Level 3aTreatment being tested
Azer-cel, 3 x 10\^6 CAR T cells per kg body weight. Route of Administration: Intravenous infusion
Treatment: Azer-cel, Fludarabine, and Cyclophosphamide
- Phase 1 Dose Escalation: Azer-cel Dose Level 4Treatment being tested
Azer-cel, 6 x 10\^6 CAR T cells per kg body weight as 2 administrations of 3 x 10\^6 CAR T cells per kg body weight on Day 0 and Day 10. Route of Administration: Intravenous infusion
Treatment: Azer-cel, Fludarabine, and Cyclophosphamide
- Phase 1 Dose Escalation: Azer-cel Dose Level 4bTreatment being tested
Azer-cel, 500 x 10\^6 CAR T cells (flat dose). Route of Administration: Intravenous infusion
Treatment: Azer-cel, Fludarabine, and Cyclophosphamide
- Phase 1B Dose Expansion: Azer-celTreatment being tested
Azer-cel will be administered at a dose level established in Phase 1. Route of Administration: Intravenous infusion
Treatment: Azer-cel, Fludarabine, Cyclophosphamide, and IL-2
- Phase 1B Dose Expansion: Azer-cel + Bruton's tyrosine kinase inhibitorTreatment being tested
Azer-cel will be administered at a dose level established in Phase 1. Route of Administration: Intravenous infusion In combination with a Bruton's tyrosine kinase inhibitor
Treatment: Azer-cel, Fludarabine, Cyclophosphamide, IL-2, and Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Plain-language title
- Testing azer-cel, a donor-derived CAR T therapy, in adults with relapsed blood cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 8 September 2026